Marketing-authorisation holder · United States
Avyxa Holdings
11 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
11 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AVGEMSI1gm base/26.3ml (eq 38mg base/ml) | 200mg base/5.26ml (eq 38mg base/ml) | 2gm base/52.6ml (eq 38mg base/ml) · Solution | Gemcitabine | United States | Marketed | 2025 |
| AVOPEF100mg/5ml (20mg/ml) · Solution | Etoposide | United States | Marketed | 2026 |
| AXTLE100mg base/vial | 500mg base/vial · Powder | Pemetrexed | United States | Marketed | 2024 |
| BENDAMUSTINE HYDROCHLORIDE100mg/4ml (25mg/ml) | 200mg/8ml (25mg/ml) | 25mg/ml (25mg/ml) · Solution | Bendamustine | United States | Marketed | 2021 |
| CLIGAVYX250mg/5ml (50mg/ml) · Solution | Fulvestrant | United States | Not marketed | 2019 |
| DOCIVYX160mg/16ml (10mg/ml) | 20mg/2ml (10mg/ml) | 80mg/8ml (10mg/ml) · Solution | Docetaxel | United States | Marketed | 2022 |
| FAVLYXA250mg/10ml (25mg/ml) · Solution | Fluorouracil | United States | Marketed | 2026 |
| FRINDOVYX1gm/2ml (500mg/ml) | 2gm/4ml (500mg/ml) | 500mg/ml (500mg/ml) · Solution | Cyclophosphamide | United States | Marketed | 2023 |
| KYXATA20mg/2ml (10mg/ml) | 500mg/50ml (10mg/ml) | 80mg/8ml (10mg/ml) · Solution | Carboplatin | United States | Marketed | 2025 |
| POSFREA0.075mg base/1.5ml (eq 0.05mg base/ml) | 0.25mg base/5ml (eq 0.05mg base/ml) · Solution | Palonosetron | United States | Marketed | 2016 |
| VYKOURA350mg base/35ml (eq 10mg base/ml) | 500mg base/50ml (eq 10mg base/ml) | 50mg base/5ml (eq 10mg base/ml) · Solution | Calcium folinate | United States | Marketed | 2026 |